5 citations
,
December 2022 in “Viruses” This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.
This review summarizes the latest updates on using antiandrogens as potential prophylactic and therapeutic options for COVID-19, highlighting that androgen-mediated regulation of factors like TMPRSS2 and ACE2 is involved in SARS-CoV-2 infection, suggesting a strategy to block viral entry into cells.
6 citations
,
January 2024 in “Cancers” This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.
12 citations
,
August 2020 in “Annals of Oncology” This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.
October 2020 in “Проблемы эндокринологии” This review discusses the potential roles of androgens and antiandrogens in COVID-19 outcomes, noting unresolved questions about their effectiveness and safety for treatment.